THERAPY DOSSIER · th-051d5a96cb52

Functionalised self-assembling peptide hydrogel Ac-FAQ based on LDLK12

Device

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 22476090 ↗2012Reported benefit

New bioactive motifs and their use in functionalized self-assembling peptides for NSC differentiation and neural tissue engineering.

MixedSpinal cord injuryContusionImplantation of the hydrogel scaffold at the injury site

Model: Acute contusive spinal cord injury

The functionalised self-assembling peptide Ac-FAQ supported the highest neural stem cell viability and differentiation in vitro and, when implanted after contusive spinal cord injury, promoted nervous tissue regrowth and improved locomotor recovery. Non-functionalised LDLK12 gave intermediate axon…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…